<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238871</url>
  </required_header>
  <id_info>
    <org_study_id>C15-64</org_study_id>
    <nct_id>NCT04238871</nct_id>
  </id_info>
  <brief_title>PID (RaDiCo Cohort)</brief_title>
  <acronym>RaDiCo PID</acronym>
  <official_title>Idiopathic Interstitial Pneumopathy : Genetic and Environmental Determinants From Infancy to Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to describe the phenotypic features of the paediatric and adult
      patients with Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse (IIP/PID),
      at diagnosis and during the follow-up. These data will be critical for the description of the
      natural history of the various forms of IIP/PID.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The French RaDiCo-IIP/PID (Idiopathic Interstitial Pneumopathy registry is an ongoing
      observational prospective and retrospective cohort with longitudinal long-term follow-up
      includes pediatric and adult patients with Idiopathic Interstitial Lung Disesa (ILD) from the
      reference and competence centers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">September 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The phenotypic description idiopathic lung disease</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Phenotypic description will be measure demographic data, environmental data, socio-professionnal data, medical history, comorbidities, clinical examination, biological assessment (hematology; biochemistry; hemostasis...), pulmonary biopsy, bronchial-pulmonary imaging; symptom description; respiratory function (arterial blood gas, pulmonary fonction testing, six minute-walk testing, cardiopulmonary exercise testing, polysomnography), treatments, quality of life questionnaire (SF36 and SF10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify gene factors involved in disease initiation and progression</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>study genes : SFTPA1, SFTPA2, SFTPB, SFTPC, ABCA3, NKX-2.1, TERT, TERC, RTEL1, PARN, DKC1, TINF2, COPA, MARS, CSF2RA, CSF2RB, SERPINA1, FLCN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the extent to which environmental and co-morbidity factors may influence disease severity and outcome</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>environnemental data: dwellings, wet areas, dust, smoking, drugs, exposure to materials. Respiratory history, cardiovascular history, endocrinal history, dermatological history, gastroenterology history, gynecology history, haematological history, immune history, neurological history, ophtalmological history, ENT history, psychatric history, Rheumatology history, surgery history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify and validate biomarkers for disease diagnosis and progression</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Identify and validate biomarkers for disease diagnosis and progression with Biological assessment (professionnal data, medical history, comorbidities, clinical examination, biological assessment (hematology; biochemistry; hemostasis...) and respiratory function (arterial blood gas, pulmonary fonction testing, six minute-walk testing, cardiopulmonary exercise testing, polysomnography)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse</condition>
  <condition>Paediatric and Adult Patients</condition>
  <arm_group>
    <arm_group_label>children or adults with Idiopathic Lung Disease</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a diagnosis of Pneumopathie Interstitielle Diffuse/ Idiopathic Interstitial
        Pneumonia diagnosis is established on presenting history, clinical, radiological and
        functional and if available pathological findings.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical criteria: chronic respiratory insufficiency manifestations including
             dyspnea/tachypnea, cough, and cyanosis during exercise or at rest

          -  Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT)
             abnormalities including widespread ground glass or alveolar attenuation, reticulation
             often associated with traction bronchiectasis, and honeycombing

          -  Functional criteria: pulmonary function test abnormalities reflecting a restrictive
             pattern and including: loss of lung volume, vital capacity (VC), total lung capacity
             (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas
             exchange abnormalities, and altered ventilatory response to exercise

          -  Patients (parents/guardians for paediatric/patients) having given an informed consent
             to participate in the protocol

          -  Patients affiliated to the &quot;Regime National d'Assurance Maladie&quot;

        Exclusion Criteria:

          -  Patients with diffuse parenchymal lung diseases caused by drug toxicity,
             immunodeficiency, proliferative disorders including histiocytosis, and metabolic
             disorders

          -  Patients (parents/guardians for paediatric patient) not able to approve/understand the
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie Chevereau</last_name>
    <phone>+ 33 1 71 73 87 94</phone>
    <email>marie.chevereau@radico.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonia Gueguen</last_name>
    <phone>+33 6 88 34 54 08</phone>
    <email>sonia.gueguen@radico.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Lyon - Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Cottin, Pr</last_name>
      <email>vincent.cottin@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick Clément, Pr</last_name>
      <email>annick.clement@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

